| |
| |
|
| Insider
Information: |
Weaver Gregory L |
| Relationship: |
Chief Financial Officer |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
51,152 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$47,312 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
51,152 |
|
|
| Total
Value |
$47,312 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
0.0
|
| Percentage
Gain/Loss : |
 -72.3%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Adhera Therapeutics, Inc |
ATRX |
Chief Financial Officer |
2005-05-25 |
16,000 |
2004-06-09 |
0 |
Premium* |
|
|
Celsion Corp |
CLSN |
CFO |
2013-03-19 |
0 |
2007-02-23 |
0 |
Premium* |
|
|
Poniard Pharmaceuticals |
PARD |
Chief Financial Officer |
2009-08-21 |
10,000 |
|
0 |
Premium* |
|
|
Atossa Genetics Inc |
ATOS |
Former EVP, CFO, & Dir... |
2023-11-15 |
55 |
2013-10-10 |
0 |
Premium* |
|
|
Fibrocell Science Inc |
FCSC |
Chief Financial Officer |
2013-11-20 |
10,000 |
2013-11-20 |
0 |
Premium* |
|
|
Eloxx Pharmaceuticals Inc |
ELOX |
|
2020-03-15 |
10,431 |
2018-03-23 |
0 |
Premium* |
|
|
Atai Life Sciences B.v. |
ATAI |
Chief Financial Officer |
2021-06-22 |
4,666 |
2021-06-22 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ATOS |
Atossa Genetics Inc |
Former EVP, CFO, & Director |
• • – |
2023-11-15 |
4 |
S |
$0.65 |
$32,500 |
D/D |
(50,000) |
55 |
0 |
- |
|
| ATOS |
Atossa Genetics Inc |
Director |
• • – |
2021-07-02 |
4 |
S |
$5.58 |
$599,833 |
D/D |
(107,497) |
0 |
0 |
- |
|
| ATOS |
Atossa Genetics Inc |
Director |
• • – |
2021-07-02 |
4 |
D |
$6.40 |
$365,338 |
D/D |
(57,084) |
107,497 |
0 |
- |
|
| ATOS |
Atossa Genetics Inc |
Director |
• • – |
2021-07-02 |
4 |
OE |
$1.70 |
$365,337 |
D/D |
164,581 |
164,581 |
0 |
- |
|
| ATAI |
Atai Life Sciences B.v. |
Chief Financial Officer |
• – – |
2021-06-22 |
4 |
B |
$15.00 |
$69,990 |
D/D |
4,666 |
4,666 |
2.74 |
% |
|
| ELOX |
Eloxx Pharmaceuticals Inc |
FORMER CHIEF FINANCIAL OFFICER |
– – – |
2020-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,750 |
11,517 |
0 |
- |
|
| ELOX |
Eloxx Pharmaceuticals Inc |
FORMER CHIEF FINANCIAL OFFICER |
– – – |
2020-03-15 |
4 |
D |
$2.85 |
$3,095 |
D/D |
(1,086) |
10,431 |
0 |
- |
|
| ELOX |
Eloxx Pharmaceuticals Inc |
CHIEF FINANCIAL OFFICER |
• – – |
2020-01-30 |
4 |
D |
$3.91 |
$6,776 |
D/D |
(1,733) |
7,767 |
0 |
- |
|
| ELOX |
Eloxx Pharmaceuticals Inc |
CHIEF FINANCIAL OFFICER |
• – – |
2020-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
9,500 |
0 |
- |
|
| ELOX |
Eloxx Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2018-03-23 |
4 |
B |
$8.56 |
$38,520 |
D/D |
4,500 |
4,500 |
2.74 |
- |
|
| ATOS |
Atossa Genetics Inc |
Director |
– • – |
2014-05-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(24,510) |
0 |
0 |
- |
|
| ATOS |
Atossa Genetics Inc |
Director |
– • – |
2013-11-21 |
4 |
B |
$2.58 |
$25,785 |
D/D |
10,000 |
34,510 |
2.39 |
- |
|
| FCSC |
Fibrocell Science Inc |
Chief Financial Officer |
• – – |
2013-11-20 |
4 |
B |
$3.51 |
$35,080 |
D/D |
10,000 |
10,000 |
2.74 |
- |
|
| ATOS |
Atossa Genetics Inc |
Director |
– • – |
2013-10-10 |
4 |
A |
$0.00 |
$0 |
D/D |
24,510 |
24,510 |
0 |
- |
|
| CLSN |
Celsion Corp |
CFO |
• – – |
2013-03-19 |
4 |
S |
$1.06 |
$39,508 |
D/D |
(37,272) |
0 |
0 |
- |
|
| CLSN |
Celsion Corp |
SVP & Chief Financial Officer |
• – – |
2012-12-18 |
4 |
OE |
$2.77 |
$23,922 |
D/D |
8,636 |
37,272 |
0 |
- |
|
| CLSN |
Celsion Corp |
CFO |
• – – |
2011-12-06 |
4 |
B |
$2.15 |
$10,750 |
D/D |
5,000 |
28,636 |
2.74 |
- |
|
| CLSN |
Celsion Corp |
Director |
– • – |
2011-05-26 |
4 |
B |
$2.77 |
$23,922 |
D/D |
8,636 |
23,636 |
2.39 |
- |
|
| CLSN |
Celsion Corp |
Director |
– • – |
2010-09-16 |
4 |
B |
$3.10 |
$15,500 |
D/D |
5,000 |
15,000 |
2.39 |
- |
|
| PARD |
Poniard Pharmaceuticals |
Chief Financial Officer |
• – – |
2009-08-21 |
4 |
B |
$7.39 |
$22,179 |
D/D |
3,000 |
10,000 |
2.74 |
- |
|
| PARD |
Poniard Pharmaceuticals |
Chief Financial Officer |
• – – |
2009-04-06 |
4 |
B |
$2.05 |
$4,143 |
D/D |
2,000 |
7,000 |
2.66 |
- |
|
| PARD |
Poniard Pharmaceuticals |
Chief Financial OfficerOfficer |
• – – |
2009-02-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,000 |
|
- |
|
| CLSN |
Celsion Corp |
Director |
– • – |
2007-02-23 |
4 |
B |
$3.50 |
$35,000 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| ATRX |
Adhera Therapeutics, Inc |
Chief Financial Officer |
• – – |
2005-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
16,000 |
|
- |
|
| ATRX |
Adhera Therapeutics, Inc |
Chief Financial Officer |
• – – |
2004-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
8,500 |
|
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
